These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 26351332)

  • 1. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC
    J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer.
    Leung HWC; Chan ALF; Muo CH; Leung JH
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):207-213. PubMed ID: 28965422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
    Hassett MJ; Li H; Burstein HJ; Punglia RS
    Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.
    Fleeman N; Bagust A; Beale S; Dwan K; Dickson R; Proudlove C; Dundar Y
    Pharmacoeconomics; 2015 Jan; 33(1):13-23. PubMed ID: 25138171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.
    Cheng LJ; Loke L; Lim EH; Pearce F; Aziz MIA; Ng K
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):449-456. PubMed ID: 33595372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan.
    Diaby V; Alqhtani H; van Boemmel-Wegmann S; Wang CY; Ali AA; Balkrishnan R; Ko Y; Palacio S; de Lima Lopes G
    Breast; 2020 Feb; 49():141-148. PubMed ID: 31805500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.
    Diaby V; Adunlin G; Ali AA; Zeichner SB; de Lima Lopes G; Kohn CG; Montero AJ
    Breast Cancer Res Treat; 2016 Nov; 160(1):187-196. PubMed ID: 27654970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
    Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D
    Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.
    Diaby V; Ali AA; Williams KJ; Ezendu K; Soto-Perez-de-Celis E; Chavarri-Guerra Y; de Lima Lopes G
    Breast Cancer Res Treat; 2017 Dec; 166(3):951-963. PubMed ID: 28840424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
    Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
    JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
    Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
    N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
    Le QA; Bae YH; Kang JH
    Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in Colombia.
    Guevara-Cuellar CA; Parody-Rúa E; Rengifo-Mosquera MP; Del Mar Conde-Crespo M; Nuñez-Castro JM
    Value Health Reg Issues; 2022 Nov; 32():109-118. PubMed ID: 36183606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Squires H; Pandor A; Thokala P; Stevens JW; Kaltenthaler E; Clowes M; Coleman R; Wyld L
    Pharmacoeconomics; 2018 Jan; 36(1):29-38. PubMed ID: 28770452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer.
    Jiao B; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):497-504. PubMed ID: 33645393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore.
    Lim EH; Lim A; Khara JS; Cheong J; Fong J; Sivanesan S; Griffiths M; New E; Lee SC
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):413-426. PubMed ID: 38289042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.
    Dai WF; Beca JM; Nagamuthu C; Liu N; de Oliveira C; Earle CC; Trudeau M; Chan KKW
    JAMA Oncol; 2022 Apr; 8(4):597-606. PubMed ID: 35201264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.